Clyra expands ViaCLYR distribution to U.S. government healthcare facilities worldwide

Clyra Medical Technology has signed an exclusive purchasing agreement with Spartan Medical to resell ViaCLYR wound irrigation to government healthcare facilities worldwide, including VA and Defense Department sites. The deal expands access to the FDA-cleared antimicrobial as Clyra pushes into federal care settings where wound management is a priority.

Why it matters: - The agreement opens a new distribution path for ViaCLYR into federal healthcare systems that treat veterans, service members and other patients with complex wound-care needs. - The product’s addition to government purchasing channels could broaden use across VA, DoD and other federal facilities that need infection-control options with persistent antimicrobial activity. - Clyra is pairing its wound-care technology with Spartan Medical’s government contracting footprint to speed adoption in public-sector care settings.

What happened: - Clyra Medical Technology announced an exclusive purchasing agreement with Spartan Medical to resell ViaCLYR advanced wound irrigation solution to government healthcare facilities worldwide. - The announcement was made Sept. 2, 2026, from Tampa, Florida. - ViaCLYR is now available for resale to VA/DoD-operated or managed facilities, Federal Bureau of Prisons facilities, Indian Health Service facilities, other federal agency healthcare facilities and certain civilian hospitals operating under VA Community Care or VA-funded contracts. - ViaCLYR has been added to the Defense Logistics Agency Electronic Catalog.

The details: - ViaCLYR is powered by Clyrasept Copper-Iodine Complex Solution Complex, which Clyra describes as a broad-spectrum antimicrobial designed for speed, efficacy, persistence and biocompatibility. - In clinical tests, ViaCLYR killed 99.9999% of 18 pathogens within one minute of application. - The product is effective against MRSA, VRE and Candida auris. - ViaCLYR provides 72-hour antimicrobial management without reapplication. - The solution is non-cytotoxic and does not require rinsing. - Clyra says standard wound care solutions often persist for 60 seconds or less and require repeated reapplication and wound dressing changes. - ViaCLYR is FDA 510(k)-cleared for cleansing, irrigating and debriding a wide range of wound types, including first- and second-degree burns, Stage I–IV pressure ulcers, diabetic and stasis ulcers, post-surgical wounds and abrasions. - The clearance also covers moistening and lubricating absorbent wound dressings. - Clyra Medical Technologies is a subsidiary of BioLargo Inc. (OTCQX: BLGO). - Clyra was founded in 2012 and focuses on infection control and advanced wound care. - Spartan Medical is a veteran-owned-and-operated government contractor for the Department of Veterans Affairs, the Department of Defense and other public agencies.

Between the lines: - The deal gives Clyra access to procurement channels that can be difficult for smaller medical companies to enter without a government-focused distributor. - Spartan Medical’s emphasis on veteran and military care matches ViaCLYR’s targeted use case in wound management and infection control. - Clyra’s “parity pricing” pitch suggests the company is trying to compete on both performance and procurement economics. - The company’s broad claims about being the “first-ever” antimicrobial and becoming a standard of care are forward-looking and not independently verified in the release.

What's next: - ViaCLYR can now be ordered through Spartan Medical for eligible government and federal healthcare customers. - Clyra will likely use the distribution agreement and ECAT listing to expand penetration across VA, DoD and related facilities. - The company expects the product to see broader adoption in settings where wound care and infection prevention are clinically important.

The bottom line: - Clyra is using a government-focused distribution partner and federal procurement listings to push ViaCLYR deeper into public healthcare markets.